Ion Beam Applications S.A.

IBA- Ion Beam Applications develops and markets technologies and pharmaceutical products for the healthcare sector, with a focus on cancer diagnosis and therapy. Co. is also engaged in the sterilization and ionization market. Co. operates in two primary business segments: Equipment and Pharmaceuticals. Co.'s Equipment segment encompasses development, fabrication, and services associated with medical and industrial particle accelerators, proton therapy systems, and a range of dosimetry products, while Co.'s Pharmaceuticals segment encompasses the production and distribution of radiopharmaceutical agents as well as its bioassay operations.
  • TickerIBAB
  • ISINBE0003766806
  • ExchangeEuronext Brussels
  • SectorHealth Care Equipment & Services
  • CountryBelgium
ING
ING Helpdesk

Benelux Morning Notes

ABN AMRO: Impairment outlook worse than expected. Ageas: Withdrawing 2020 guidance should not be a surprise. Agfa-Gevaert: AGM and EGM feedback. Bekaert: 1Q20 sales -11%, limited visibility on depth and duration through. Boskalis: Qualitative trading update just after Covid-19 update. Colruyt: Matching lowest prices with home delivery. IBA: Reassuring 1Q20 qualitative update on operations, cash. Kinepolis: 1Q20 visitors down 9% on lockdowns, client caution. Belgium better. PostNL: virtual management roadshow - feedback and highlights. SBM Offshore: MODEC's pain is not SBM's....

Bart Cuypers ...
  • Guy Sips
  • Jason Kalamboussis
  • Lenny Van Steenhuyse
  • Wido Jongman
  • Wim Hoste

Morning Note: ABN NA, AGS BB, AGFB BB, BEKB BB, CFEB BB, IBAB BB, KIN BB, RET BB, TEXF BB

ABN Amro: 1Q: LLPs +42% above estimates says it all Ageas: 1Q ok, cautious guidance. Asia better, UK struggles Agfa: Focus on securing future and investments in growth Bekaert: 1Q consolidated sales -11% CFE: Fehmarnbelt set to start early 2021 IBA: COVID-19 delays kick in Kinepolis: 1Q impacted by closure of cinemas from mid-March Retail Estates: Positive COVID-19 update Texaf: AGM feedback: COVID-19 impact seems limited

ING
Albert Ploegh, CEFA ...
  • David Vagman, CFA
  • Hans D’Haese
  • Marc Hesselink, CFA
  • Marc Zwartsenburg, CEFA
  • Maxime Stranart
  • Quirijn Mulder
  • Reginald Watson, CFA
  • Stijn Demeester
  • Tijs Hollestelle

Benelux thematic equity research/Covid-19 scenario analysis

The ING Benelux equity research team has performed a Covid-19 scenario analysis in order to provide a reference point for investors and to test if stocks: (a) have been relatively oversold in comparison to their earnings risk; (b) still provide downside risk; and/or have balance issues in a Covid-19 scenario; and (c) could bounce sharply if a vaccine is found; or (d) benefit relatively from the crisis. Our analysis results in lists of stocks that we consider: (1) low earnings risk, with attractive risk-reward; (2) high earnings risk but already heavily sold off; (3) to have downside risk and/o...

IBA: 1 director sold

A director at IBA sold 2,365 shares at 7.760EUR and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members alon...

Bart Cuypers ...
  • Cedric Duinslaeger
  • Guy Sips
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Michiel Declercq
  • Ruben Devos
  • Sandra Cauwenberghs
  • Wido Jongman

Morning Note: BRNL NA, EXM BB, HAL NA, IBAB BB, JEN BB, SOF BB, TNET BB, WDP BB

Brunel International: Update on COVID-19 impact EXMAR: FY19 results in line, FSRU still in arbitrage Hal Trust: FY19: GV & Vopak pushing up NAV IBA: Ready to weather the storm if needed Jensen-Group: COVID-19: manageable but significant FY20 impact Sofina: Quality Comes at a Price Telenet: Maintains gross final DPS of € 1.30 WDP: Covid-19 update

Tolu Alamutu CFA

International Bank of Azerbaijan: Unfinished business

Our Hold recommendation on the International Bank of Azerbaijan (IBAZAZ) 3.5% 2024 bond is unchanged. IBAZAZ has been refused the right to appeal previous judgements upholding the rights of certain holders of the IBAZAZ 5.625% 2019 bond by the UK Supreme Court. This is according to a press release issued by Dechert, the law firm representing the bondholders. As we have previously noted, the bondholders’ claim relied on an 1890 precedent, known as the Gibbs case. The press release disclosed a claim of ‘more than US$170 million’ now due to bondholders. This compares with the total amount issued ...

ION BEAM APPLICATIONS SA sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of ION BEAM APPLICATIONS SA (BE), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date April 21, 2020, the closing price was EUR 7.42 and its target price was estimated at EUR 6.37.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch